JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (2): 12-18.doi: 10.6040/j.issn.1671-7554.0.2014.614

Previous Articles     Next Articles

Effects of statins on patients with chronic obstructive pulmonary disease: a Meta analysis

WU Zhen1, SONG Guodong2, WANG Wei1   

  1. 1. Department of Respiratory, the Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    2. Peking Union Medical College, Beijing 100730, China
  • Received:2014-09-17 Online:2015-02-10 Published:2015-02-10

PDF (PC)

239

Abstract: Objective To evaluate the effects of statins treatment on pulmonary function, exacerbation, inflammatory factors, and health conditions in stable patients with chronic obstructive pulmonary disease (COPD). Methods Databases of PubMed, Cochrane Library, CNKI, Wanfang and VIP were searched up from the day of database construction to November, 2014. Randomized controlled trials (RCTs) which investigated the effects of statins treatment on stable COPD patients were identified. Two independent reviewers screened the retrieved literatures, measured the quality, extracted the data and cross-checked them. RevMan 5.2 statistical software was used to analysis the data. Results Twelve RCTs, including 1 589 patients, were included. Statins treatment reduced the levels of blood inflammatory factors, including serum CRP (WMD:-1.62; 95%CI:-1.90 to -1.34), plasma TNF-α(WMD: -5.31; 95%CI:-9.45 to -1.17) and serum IL-6 (WMD:-0.46; 95%CI:-0.89 to -0.03), alleviated the clinical symptoms, reduced the degree of dyspnea, and improved the life quality. Statins treatment could not improve the forced expiratory volume in 1 second (FEV1), FEV1% predicted (FEV1%pred) and exacerbation. Conclusion Statins treatment has anti-inflammatory effects and can alleviate clinical symptoms, but has no significant effects on reversing the decline of pulmonary function and preventing exacerbation in stable COPD patients.

Key words: Pulmonary disease, chronic obstructive, Statin, Meta analysis, Stable

CLC Number: 

  • R563
[1] World Health Organization. World health statistics 2008[EB/OL]. http://www.who.int/whosis/ whostat/EN_WHS08_Full.pdf, 2008-05-20/2013-12-10.
[2] Olivo SA, Macedo LG, Gadotti IC, et al. Scales to assess the quality of randomized controlled trials:a systematic review [J]. Phys Ther, 2008, 88(2):156-175.
[3] Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD [J]. N Engl J Med, 2014, 370(23):2201-2210.
[4] Moosavi SA, Raji H, Faghankhani M, et al. Evaluation of the effects of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive pulmonary diseases:a randomized controlled trial [J]. Iran Red Crescent Med J, 2013, 15(8):649-654.
[5] Kaczmarek P, Sladek K, Skucha W, et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease [J]. Pol Arch Med Wewn, 2010, 120(1-2):11-17.
[6] Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin[J]. Am J Cardiol, 2008, 101(4):530-535.
[7] 陈植涛,唐盛发.辛伐他汀对COPD稳定期患者的干预作用临床研究[J].右江民族医学院学报, 2011, 33(4):420-422. CHEN Zhitao, TANG Shengfa. The effects of simvastatin intervention in patients with chronic obstructive pulmonary disease in stationary phase [J]. Journal of Youjiang Medical University for Nationalities, 2011, 33(4):420-422.
[8] 蒋智敏,历风元,童旭芳,等.辛伐他汀对慢性阻塞性肺疾病肺功能的影响及作用机制研究[J].海南医学, 2013, 24(9):1277-1279. JIANG Zhimin, LI Fengyuan, TONG Xufang, et al. Effect of simvastatin on pulmonary function in patients with chronic obstructive pulmonary disease in stationary phase and study on mechanism[J]. Hainan Medical Journal, 2013, 24(9):1277-1279.
[9] 金雪梅,李晓佳.辛伐他汀治疗慢性阻塞性肺疾病患者疗效观察[J].临床肺科杂志, 2011, 16(7):1012-1014. JIN Xuemei, LI Xiaojia. Curative effect observation of simvastatin treatment of chronic obstructive pulmonary disease [J]. Journal of Clinical Pulmonary Medicine, 2011, 16(7):1012-1014.
[10] 门雪琳,王永瑞.辛伐他汀对慢性阻塞性肺病患者缓解期的影响研究[J].实用心脑血管病杂志, 2011, 19(4):554-555. MEM Xuelin, WANG Yongrui. The influence of simvastatin with stable COPD patient [J]. Practical Journal of Cardiac Cerebral Pneumal And Vascular Disease, 2011, 19(4):554-555.
[11] 王永彬.辛伐他汀对COPD患者可溶性Fas及气道炎症的干预作用[D].济南:山东大学医学院,2009. WANG Yongbin. The effects of simvastatin on plasma soluble fas and airway inflammation in patients with chronic obstructive pulmonary disease[D]. Jinan: School of Medicine, Shandong University, 2009.
[12] 徐建荣,郑赣红,颜胜君,等.氟伐他汀对慢性阻塞性肺疾病稳定期患者肺功能及白细胞介素-6的影响[J].中国医药导报, 2012, 9(25):98-99. XU Jianrong, ZHENG Ganhong, YAN Shengjun, et al. The effect of fluvastatin on pulmonary function and interleukin-6 levels in patients with chronic obstructive pulmonary disease in stationary phase [J]. China Medical Herald, 2012, 9(25):98-99.
[13] 杨培文,王群,利桂河,等.阿托伐他汀治疗稳定期重度COPD的临床研究[J].临床肺科杂志, 2012, 17(6):1041-1042. YANG Peiwen, WANG Qun, LI Guihe, et al. Clinical research about the atovastatin treatment effect on stable stage of severe chronic obstructive pulmonary disease[J]. Journal of Clinical Pulmonary Medicine, 2012, 17(6):1041-1042.
[14] 张艳.辛伐他汀在COPD治疗中的临床应用研究[J].中外健康文摘, 2011, 8(47):250-251.
[15] Marzilli M. Pleiotropic Effects of Statins: evidence for benefits beyond LDL-Cholesterol lowering [J]. Am J Cardiovasc Drugs, 2010, 10(Suppl 1):3-9.
[16] Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function:VA Normative Aging Study [J]. Am J Respir Crit Care Med, 2007, 176(8):742-747.
[17] Bando M, Miyazawa T, Shinohara H, et al. An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease [J]. Respirology, 2012, 17(3):493-498.
[18] Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD:evidence from a retrospective cohort study [J]. Int J Clin Pract, 2008, 62(9):1373-1378.
[19] Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins[J]. Chest, 2007, 131(4):1006-1012.
[20] Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization [J]. Am J Med, 2013, 126(7):598-606.
[21] Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease [J]. J Am Coll Cardiol, 2006, 47(12):2554-2560.
[22] Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD:the Rotterdam study [J]. Pulm Pharmacol Ther, 2013, 26(2):212-217.
[23] 陈旭东,王伟,王永彬.辛伐他汀对COPD大鼠模型炎症的干预作用[J].山东大学学报:医学版, 2010, 48(4):36-39. CHEN Xudong, WANG Wei, WANG Yongbin. Effect of simvastatin on inflammation in chronic obstructive pulmonary disease rat model [J]. Journal of Shandong University: Health Sciences, 2010, 48(4):36-39.
[1] XU Ning-Yu, WANG Lei, HAO En-Kui, SU Guo-Hai. Effects of atorvastatin given before acute PCI on inflammatory mediators and left ventricular function in STEMI [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 69-72.
[2] GAO Xiu-Rui, ZANG Heng-Chang. In vitro release of compound niacin extended-release and simvastatin immediaterelease double-layer tablets [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 109-113.
[3] ZHANG Xinke, CHEN Hongyuan, YANG Ying, LI Yan, WANG Fengshan. Development and evaluation of chitosan gene nanoparticles loaded with recombinant plasmid pVAX1/Tat PTD-endostatin [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 43-48.
[4] SONG Yu, MAO Yang, LIU Qingmei, QIAO Lei, TIE Yuanyuan, LU Lu, ZHANG Lei. Effect of Tongxinluo on three-dimensional strain of atherosclerotic vulnerable plaque in rabbits [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 1-7.
[5] YU Xiaolin, ZHANG Jun, YANG Liu, ZHOU Lin, CUI Liangliang, ZHANG Ji. Epidemiological characteristics of COPD patients attacked by respiratory system diseases during the flu season in Jinan City [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 79-82.
[6] PAN Qing, LÜ Zhifang. Clinical application value of the new guide for patients with chronic obstructive pulmonary disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 63-67.
[7] WANG Cong, SUN Shuzhen, ZHEN Junhui, LI Qian, XU Yihuai. Role of CXCL16 in mice with adriamycin induced nephropathy and the protective effects of simvastatin [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 24-29.
[8] LI Xingyu, LIANG Jing, LI Yan. Antitumor effect of endostatin synergized with tumor special DC-T cellular therapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 19-23.
[9] YANG Juan, QIU Zongjian, SONG Qiang. Impacts of Simvastatin on DNA methyltransferase of cell line NB4 in acute myeloid leukemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(6): 28-32.
[10] TAN Bei, GUAN Yuqing, SUN Hui, HU Keqing, SU Guohai, WEI Min. Effects of atorvastatin with intravascular ultrasound on atherosclerotic plaques in rabbits [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 10-14.
[11] DUAN Ruisheng. Immune-regulation of statins in atherosclerosis and opinions on its clinical applications [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 1-4.
[12] LIN Jinxiu, SUN Dongsheng, ZHENG Xiao, YIN Dechao, LI Ye, ZHANG Lei. Enhancement of tendon-bone healing by topical use of simvastatin after ACL reconstruction [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 27-31.
[13] RONG Chunli, YAO Wenjing, YANG Qian, LI Ruyi, CAO Dongping, LIU Meixia, PENG Yingxin. Clinical efficacy of atorvastatincalcium combined with ezetimibe in the treatment of coronary atherosclerosis with hyperlipidemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(11): 46-49.
[14] TIAN Yan, HOU Shanrong, LIU Jianli, SUN Xingsheng, HUANG Lihong. Effects of different doses of atorvastatin on the content of TGF-β1 and cardiac structure of dilated cardiomyopathy rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 6-10.
[15] LI Yueyan1, GUAN Yuqing2, MIAO Wei2, HU Keqing2, HU Hongyan3, LI Ying2, WANG Xiaoqi2, SU Guohai2. Effect of atorvastatin on TLR4 expression and downstream signaling in atherosclerotic rabbits [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 1-6.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd